samedan logo
 
 
spacer
home > pmps > autumn 2008 > coated for success
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Coated for Success

As anyone in the pharma industry knows, smart money no longer bets on big returns from blockbuster drugs. As a recent PricewaterhouseCoopers report noted, new molecules are scarcer than they have been for many years. In 2007, for example, the FDA approved only 19 new molecular entities and biologics – fewer than in any year since 1983 (1).

Meanwhile, the patents protecting blockbuster molecules developed during the 1980s and 1990s are already expiring, permitting generic manufacturers to cash in on the innovators’ costly research. US research firm Sanford C. Bernstein has estimated that, due to generic market share erosion, the top 10 pharma companies will lose between two and 40 per cent of their revenue between 2008 and 2012 (1).

At the same time, the cost of developing new molecules has soared. At the 2006 Drug Discovery Conference held in Boston, it was estimated that the cost of producing a successful new drug could now exceed $2 billion (2).

ADAPT AND SURVIVE

In the face of this turmoil, pharma companies are radically adapting their businesses simply in order to survive. Two very different markets are emerging...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hans Huttinga is the Strategic Marketing Director (Pharma Ingredients) of Kerry Bioscience – Sheffield Pharma Ingredients. Hans, who has worked for the Kerry Bioscience organisation since 2000, has accrued more than 16 years of experience in new business, commercialisation and development of highly valued pharmaceutical ingredients and life science products within the life science and pharma markets. He graduated as an Engineer in Biotechnology in 1989, and has a long track record in business creation, sales and marketing within profitable companies serving the excipient and cell nutrition markets, and supplying the pharmaceutical and biotechnology industries.
spacer
Hans Huttinga
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement